US 12,251,394 B2
Methods for the treatment of bladder cancer
Dae-Shik Kim, Andover, MA (US); Frank Fang, Andover, MA (US); Atsushi Endo, Andover, MA (US); Hyeong-Wook Choi, Andover, MA (US); Ming-Hong Hao, Quincy, MA (US); Xingfeng Bao, Concord, MA (US); and Kuan-Chun Huang, Lexington, MA (US)
Assigned to Eisai R&D Management Co., Ltd., Tokyo (JP)
Appl. No. 17/058,817
Filed by Eisai R&D Management Co., Ltd., Tokyo (JP)
PCT Filed May 31, 2019, PCT No. PCT/US2019/034933
§ 371(c)(1), (2) Date Nov. 25, 2020,
PCT Pub. No. WO2019/232392, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/679,495, filed on Jun. 1, 2018.
Claims priority of provisional application 62/826,347, filed on Mar. 29, 2019.
Prior Publication US 2021/0205348 A1, Jul. 8, 2021
Int. Cl. A61K 31/7084 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/7084 (2013.01) [A61P 35/04 (2018.01)] 12 Claims
 
1. A method of treating bladder cancer, comprising administering to a patient in need of treatment an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry